Cytokinetics
CYTK
95 hedge funds and large institutions have $123M invested in Cytokinetics in 2013 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 33 increasing their positions, 28 reducing their positions, and 23 closing their positions.
198% more call options, than puts
Call options by funds: $2.99M | Put options by funds: $1M
18% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 28
6% less funds holding
Funds holding: 101 → 95 (-6)
13% less capital invested
Capital invested by funds: $141M → $123M (-$17.7M)
26% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 23
Top Buyers
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$4.27M |
| 2 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$2.99M |
| 3 |
Renaissance Technologies
New York
|
+$2.2M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$1.77M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$983K |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.9M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$3.38M |
| 3 |
Millennium Management
New York
|
-$2.05M |
| 4 |
Morgan Stanley
New York
|
-$802K |
| 5 |
GACM
Green Arrow Capital Management
New York
|
-$757K |
CYTK Hedge Fund Activity: Q4 2013 in Review
95 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q4 2013, worth a combined $123M — down 13% from $141M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of CYTK and 17 opened new positions — a net loss of 6 holders — while 28 trimmed existing stakes and 33 added.
The largest buyer was BVF Inc, adding an estimated $4.27M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $10.9M sold.
- 95 institutional investors held Cytokinetics (CYTK) as of Q4 2013, down from 101 in Q3 2013.
- Funds reported $123M of Cytokinetics stock for Q4 2013, down 13% quarter-over-quarter.
- 17 funds opened new Cytokinetics positions in Q4 2013 and 23 closed out, a net change of -6 holders.
- The largest Cytokinetics buyer in Q4 2013 was BVF Inc, an estimated $4.27M added.
- The largest Cytokinetics seller in Q4 2013 was T. Rowe Price Associates, an estimated $10.9M sold.
Based on aggregated 13F filings for Q4 2013.